Company · REGN
Regeneron Pharmaceuticals, Inc.
Name as listed on its exchange; filed with the SEC as REGENERON PHARMACEUTICALS, INC.
Nasdaq's symbol directory lists REGN on Nasdaq as “Regeneron Pharmaceuticals, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 19 occasions ($60.3M); 20 planned-sale notices; 3 congressional trade disclosures; 6 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- George L. Sing sold $22.3M
- Andrew J. Murphy, Co-Chief Scientific Officer sold $8.0M
- Huda Y. Zoghbi sold $7.9M
- Christine A. Poon sold $7.6M
- Joseph J. LaRosa, EVP General Counsel and Secret sold $4.3M
- Jason Pitofsky, SVP Controller sold $3.8M
- Marion McCourt, EVP Commercial sold $3.5M
- Michael S. Brown sold $1.7M
- Kathryn Guarini sold $1.0M
- RYAN ARTHUR F sold $130K
Every trade (19)
- SELLAndrew J. Murphy, Co-Chief Scientific Officer sold $4.8M
- SELLGeorge L. Sing sold $958K
- SELLGeorge L. Sing sold $960K
- SELLMarion McCourt, EVP Commercial sold $544K
- SELLJason Pitofsky, SVP Controller sold $3.8M
- SELLHuda Y. Zoghbi sold $7.2M
- SELLGeorge L. Sing sold $20.4M
- SELLChristine A. Poon sold $7.6M
- SELLJoseph J. LaRosa, EVP General Counsel and Secret sold $4.3M
- SELLMichael S. Brown sold $1.7M
- SELLMarion McCourt, EVP Commercial sold $984K
- SELLKathryn Guarini sold $360K
- SELLAndrew J. Murphy, Co-Chief Scientific Officer sold $3.2M
- SELLMarion McCourt, EVP Commercial sold $970K
- SELLMarion McCourt, EVP Commercial sold $1.0M
- SELLKathryn Guarini sold $340K
- SELLHuda Y. Zoghbi sold $640K
- SELLKathryn Guarini sold $320K
- SELLRYAN ARTHUR F sold $130K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- MURPHY ANDREW J $4.8M
- GEORGE L. SING $958K
- GEORGE L. SING $960K
- McCourt Marion $545K
- Jason Pitofsky $3.8M
- Jason Pitofsky $175K
- Huda Zoghbi $7.2M
- GEORGE L. SING $20.4M
- Christine Poon $7.5M
- Joseph LaRosa $4.3M
- MICHAEL S BROWN $1.6M
- McCourt Marion $984K
- Guarini Kathryn $360K
- MURPHY ANDREW J $3.2M
- McCourt Marion $969K
- McCourt Marion $1.0M
- Guarini Kathryn $340K
- Zoghbi Huda Y $640K
- Guarini Kathryn $320K
- Arthur F. Ryan $250K
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Gilbert Cisneros (D-CA31): Sale $1,001 - $15,000
- Alan Armstrong (R-OK): Purchase $1,001 - $15,000
- Julia Letlow (R-LA05): Purchase $1,001 - $15,000
Executive branch · OGE Form 278-T
Reported by the President
8 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports
- Purchase: REGENERON PHARMACEUTICALS INC $50,001 – $100,000
- Purchase: REGENERON PHARMACEUTICALS INC $1,001 – $15,000
- Sale: REGENERON PHARMACEUTICALS INC $1,001 – $15,000
- Sale: REGENERON PHARMACEUTICALS INC $100,001 – $250,000
- Purchase: REGENERON PHARMACEUTICALS INC $100,001 – $250,000
- Purchase: REGENERON PHARMACEUTICALS INC $15,001 – $50,000
- Purchase: REGENERON PHARMACEUTICALS INC $1,001 – $15,000
- Purchase: REGENERON PHARMACEUTICALS INC $1,001 – $15,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Oct 30, 2026
- Entry into a material definitive agreement; Results of operations and financial condition; Other events Oct 6, 2026
- Departure or appointment of directors or officers Sep 30, 2026
- Results of operations and financial condition Jul 30, 2026
- Results of operations and financial condition Jul 6, 2026
- Submission of matters to a vote of security holders Jun 17, 2026
Lobbying · Senate LDA reports
Lobbying filed
12 quarterly lobbying reports for 2026 naming Regeneron Pharmaceuticals, Inc. as the client: 2 filed by the company itself, 10 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- The company itself $630K
- BGR GOVERNMENT AFFAIRS $90K
- CHECKMATE GOVERNMENT RELATIONS $90K
- CRANE STRATEGIES $50K
- ARNOLD & PORTER KAYE SCHOLER LLP $50K
- THE WASHINGTON TAX & PUBLIC POLICY GROUP $30K
- The company itself $640K
- BGR GOVERNMENT AFFAIRS $90K
- CHECKMATE GOVERNMENT RELATIONS $90K
- CRANE STRATEGIES $50K
- THE WASHINGTON TAX & PUBLIC POLICY GROUP $30K
- ARNOLD & PORTER KAYE SCHOLER LLP no amount stated
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.